Additionally, the court ruled that Exelixis' pharmaceutical composition patent (U.S. 11,298,349) is not invalid and not infringed by MSN's proposed ANDA product. "We are pleased with the court's ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No.

Ipsen and Exelixis could expand the use of blockbuster oncology drug Cabometyx into prostate cancer, based on data from a phase 3 study – and help bring a cancer immunotherapy option to patients ...

The best logo maker helps you craft the right branding for your business - even if you've never designed a logo before. Our team of expert reviewers have tested the best free logo makers and the ...

The firm anticipates a deceleration in the year-over-year growth of Exelixis's cancer drug, Cabometyx, projecting it to a mid-single digit trend for the years 2024 and 2025. Additionally ...

The firm anticipates a deceleration in the year-over-year growth of Exelixis's cancer drug, Cabometyx, projecting it to a mid-single digit trend for the years 2024 and 2025. Additionally, concerns ...

This project is now archived, all future development is now on our new python installer which has more features etc. See the new project here: https://github.com ...